LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies

VANCOUVER, BC / ACCESS Newswire / December 11, 2025 / LIR Life Sciences Corp. (CSE:SKNY)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company") announces that it has filed a provisional patent application intended to cover a needle-free delivery platform for GLP/GIP[1]-based therapies used in obesity and metabolic disease. LIR filed the provisional patent application titled "Transdermal and Lingual Delivery System for GLP-1 Inhibitors" with the United States Patent and Trademark Office (USPTO). The filing is intended to protect LIR's approach to delivering these therapies through the skin, with the goal of replacing or reducing the need for injections.

The provisional application describes how established GLP/GIP drugs for obesity and type 2 diabetes can be paired with proprietary carrier technology to cross the outer layer of the skin and reach the bloodstream at therapeutic levels. This includes transdermal formats such as patches, creams or gels. The filing encompasses both the specific compositions and the methods of administration for GLP/GIP-based therapies and related peptide drugs.

From a development perspective, this provisional patent application is intended to support LIR's broader strategy to build a platform, rather than a single product. By focusing on the GLP/GIP class as a whole, the technology is intended to be compatible with multiple existing and future GLP- and GIP-based medicines, and to support potential combination products.

The provisional application also complements the Company's ongoing preclinical program, including the controlled comparative mouse study recently announced by LIR (see Company press release December 10, 2025). That study is designed to test whether a CPP-enabled, skin-applied formulation of a GLP/GIP-based therapy can achieve meaningful biological activity in a small animal model using a standard glucose tolerance test. Data from such studies are expected to inform final formulation choices and to support the transition from provisional protection into longer-term patent coverage and potential IND-enabling work.

For patients and health systems, the long-term objective of this program is to make high impact GLP/GIP-based obesity treatments easier to start and easier to stay on. Needle-free, skin-applied options could reduce the burden of repeated injections, improve adherence in real-world use and expand access in settings where injectable programs are more difficult to sustain.

"Filing of this provisional patent application is a step towards securing protection for our delivery platform, which is essential as we progress the design of formulations capable of moving GLP/GIP-based therapies through the skin and into systemic circulation," said Edward Mills, CEO of LIR Life Sciences.

AboutLIR Life Sciences Corp.

LIR Life Sciences is focused on researching and developing scalable and affordable treatments for obesity using novel drug delivery methods. The company is advancing a transdermal patch and other novel delivery systems that mimic GLP-1, a naturally occurring hormone that helps regulate appetite and blood sugar. These therapies could potentially offer an alternative to injectable drugs. The goal is to improve access, adherence, and cost-efficiency in both developed and emerging markets. LIR Life Sciences aims to address the global burden of obesity with practical solutions based on established compounds and proven science.

ON BEHALF OF LIR LIFE SCIENCES CORP.,

"Dr.Edward Mills,"

Chief Executive Officer

For more information, please contact:

Dr. Edward Mills
Chief Executive Officer
Tel: +1 888 436 7772
Email: investors@lirlife.com

Neither the CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Cautionary Note Regarding Forward-Looking Information

This news release contains statements and information that, to the extent that they are not historical fact, may constitute "forward-looking information" within the meaning of applicable securities legislation based on current expectations, estimates, forecasts, projections, beliefs and assumptions made by management of the Company. Forward-looking information is generally identified by words such as "believe", "project", "aim", "expect", "anticipate", "estimate", "intend", "strategy", "future", "opportunity", "plan", "may", "should", "will", "would", and similar expressions and, in this news release, includes statements relating to the filing of the provisional patent application, the research and development activities of the Company, the financial and business prospects of the Company, its assets and other matters. In particular, forward-looking information includes statements regarding the Company's provisional patent filings, its transdermal delivery platform, the potential compatibility of the platform with GLP/GIP-based medicines, the anticipated outcomes of preclinical studies, and the potential development of future needle-free metabolic therapies. Although the Company believes that the expectations and assumptions on which such forward- looking information are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that it will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking information in this news release. The forward-looking information included in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release is made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless so required by applicable laws.

[1]GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are both gut hormones called incretins, which are released after eating. They both work by stimulating the pancreas to release more insulin, which helps lower blood sugar levels.

SOURCE: Lir Life Sciences Corp.